TCF-1 limits the formation of Tc17 cells via repression of the MAF-RORγt axis.
Lisa A MielkeYang LiaoElla Bridie ClemensMatthew A FirthBrigette DuckworthQiutong HuangFrancisca F AlmeidaMichaël ChopinHui-Fern KoayCarolyn A BellSoroor Hediyeh-ZadehSimone L ParkDinesh RaghuJarny ChoiTracy L PutoczkiPhilip D HodgkinAshley E FranksLaura K MackayDale I GodfreyMelissa J DavisHai-Hui XueVanessa L BryantKatherine KedzierskaWei ShiGabrielle T BelzPublished in: The Journal of experimental medicine (2019)
Interleukin (IL)-17-producing CD8+ T (Tc17) cells have emerged as key players in host-microbiota interactions, infection, and cancer. The factors that drive their development, in contrast to interferon (IFN)-γ-producing effector CD8+ T cells, are not clear. Here we demonstrate that the transcription factor TCF-1 (Tcf7) regulates CD8+ T cell fate decisions in double-positive (DP) thymocytes through the sequential suppression of MAF and RORγt, in parallel with TCF-1-driven modulation of chromatin state. Ablation of TCF-1 resulted in enhanced Tc17 cell development and exposed a gene set signature to drive tissue repair and lipid metabolism, which was distinct from other CD8+ T cell subsets. IL-17-producing CD8+ T cells isolated from healthy humans were also distinct from CD8+IL-17- T cells and enriched in pathways driven by MAF and RORγt Overall, our study reveals how TCF-1 exerts central control of T cell differentiation in the thymus by normally repressing Tc17 differentiation and promoting an effector fate outcome.
Keyphrases
- induced apoptosis
- transcription factor
- dendritic cells
- cell fate
- cell cycle arrest
- regulatory t cells
- gene expression
- dna damage
- magnetic resonance
- genome wide
- immune response
- single cell
- endoplasmic reticulum stress
- stem cells
- cell therapy
- papillary thyroid
- squamous cell carcinoma
- signaling pathway
- type iii
- cell proliferation
- dna methylation
- copy number
- squamous cell
- computed tomography
- fatty acid
- lymph node metastasis